• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Fluidigm Corporation (Amendment)

    2/11/22 4:39:56 PM ET
    $FLDM
    Biotechnology: Laboratory Analytical Instruments
    Capital Goods
    Get the next $FLDM alert in real time by email
    SC 13G/A 1 d298232dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Fluidigm Corporation

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    34385P108

    (CUSIP Number)

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 34385P108    SCHEDULE 13G   

     

      1    

      Names of Reporting Persons

      Russell Investments Group, Ltd.

     

      IRS Identification No. of Above Persons (Entities Only) 98-1320542

      2  

      Check the appropriate box if a member of a Group (see instructions)

     

      (a)  ☐        (b)  ☐

     

      3  

      Sec Use Only

     

      4  

      Citizenship or Place of Organization

     

      Seattle, WA USA

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

       7  

      Sole Dispositive Power

     

       8  

      Shared Dispositive Power

     

      0

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      0.0%

    12  

      Type of Reporting Person (See Instructions)

     

      HC

     

    Page 2 of 4


    Item 1.

     

    (a)

    Name of Issuer: Fluidigm Corporation

     

    (b)

    Address of Issuer’s Principal Executive Offices:

    2 Tower Place, Suite 2000

    South San Francisco, CA 94080

     

    Item 2.

     

    (a)

    Name of Person Filing:

    Russell Investments Group, Ltd.

     

    (b)

    Address of Principal Business Office or, if None, Residence:

    1301 Second Ave, Suite 1800

    Seattle, WA 98101

     

    (c)

    Citizenship:

    Seattle, WA USA

     

    (d)

    Title and Class of Securities:

    Common Stock

     

    (e)

    CUSIP No.:

    34385P108

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a)

    ☐ Broker or dealer registered under Section 15 of the Act;

     

      (b)

    ☐ Bank as defined in Section 3(a)(6) of the Act;

     

      (c)

    ☐ Insurance company as defined in Section 3(a)(19) of the Act;

     

      (d)

    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;

     

      (e)

    ☐An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

      (f)

    ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g)

    ☒ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h)

    ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i)

    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of     1940;

     

      (j)

    ☐ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

     

      (k)

    ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.

    Ownership

     

      (a)

    Amount Beneficially Owned:

    0

     

      (b)

    Percent of Class:

    0.0%

     

    Page 3 of 4


    (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote:

    0

     

      (ii)

    Shared power to vote or to direct the vote:

    0

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    0

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    0

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

    Certain indirect clients that are advised by Russell Investments Group have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of such securities.

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

     

    Item 8.

    Identification and classification of members of the group.

     

    Item 9.

    Notice of Dissolution of Group

     

    Item 10.

    Certifications.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 10, 2022

     

    By:   /s/ Mark E. Swanson
    Name:   Mark E. Swanson
    Title:   Global Head of Fund Services

     

    Page 4 of 4

    Get the next $FLDM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FLDM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FLDM
    SEC Filings

    See more
    • Fluidigm Corporation filed SEC Form 8-K: Leadership Update

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      7/7/22 4:00:57 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Corporation filed SEC Form 8-K: Leadership Update

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/27/22 4:04:35 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/16/22 2:06:26 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Leadership Updates

    Live Leadership Updates

    See more
    • Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.

      New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focused Execution and Growth SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Fluidigm has been renamed Standard BioTools Inc. ("Standard BioTools") and its common stock is expected to begin trading on Nasdaq under

      4/4/22 5:30:57 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global

      Caligan Partners to Vote "FOR" Casdin and Viking Transaction and All Other Fluidigm Proposals at the Special Meeting to be Reconvened on April 1, 2022 Fluidigm Board to Appoint Frank Witney, a Director Candidate Recommended by Caligan, if Casdin and Viking Transaction Closes Company Urges ALL Stockholders to Vote "FOR" the Proposals at the Special Meeting SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into a support agreement with Caligan Partners LP ("Caligan"), Fluidigm's current largest holder of common stock, under which Caligan has agreed to vote "FOR" all Fluidigm proposals related to the

      3/29/22 9:29:06 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Molecular Stethoscope, Inc. establishes new Corporate Headquarters and Research & Development Laboratories in South San Francisco and appoints Gajus Worthington to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., Jan. 4, 2022 /PRNewswire/ -- Molecular Stethoscope, a leading Precision Medicine biotechnology company pioneering the next-generation cf-mRNA Liquid Biopsy, announced today that it has joined Verily Life Sciences ("Verily") partnered laboratory ecosystem in South San Francisco and appointed Gajus Worthington to its Board of Directors. The Company is now positioned to accelerate the translation of its proprietary cf-mRNA Liquid Biopsy Technology Platform to develop products and services for Precision Medicine clinical practice and biopharma R&D. "We

      1/4/22 6:00:00 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler reiterated coverage on Fluidigm with a new price target

      Piper Sandler reiterated coverage of Fluidigm with a rating of and set a new price target of $8.00 from $15.00 previously

      2/11/21 12:35:14 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Colston Bill was granted 30,914 shares, increasing direct ownership by 109% to 59,288 units

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/17/22 6:11:15 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form 4: Burbach Gerhard F was granted 30,914 shares, increasing direct ownership by 47% to 96,827 units

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/17/22 6:06:21 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form 4: Madaus Martin D was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/17/22 6:05:59 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Fluidigm Corporation (Amendment)

      SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      6/7/22 10:31:54 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form SC 13D/A filed by Fluidigm Corporation (Amendment)

      SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      5/3/22 12:40:48 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form SC 13G filed by Fluidigm Corporation

      SC 13G - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      4/14/22 5:09:34 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (f/k/a Fluidigm Corporation) (NASDAQ:FLDM) today announced, as required by Nasdaq Stock Market Rules, the grant of equity inducement awards to its new executive officers Michael Egholm, the Company's new President, Chief Executive Officer and a member of the Company's Board of Directors, and Hanjoon (Alex) Kim, the Company's new Chief Operating Officer, and a new employee, Ardalan (Alex) Arfaei, the Company's new Senior Vice President, Corporate Development. In accordance with Nasdaq Listing Rule 5635(c)(4), Standard BioTools' Compensation Committee of its Board of Directors, which is composed entirely

      4/5/22 7:15:24 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.

      New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focused Execution and Growth SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Fluidigm has been renamed Standard BioTools Inc. ("Standard BioTools") and its common stock is expected to begin trading on Nasdaq under

      4/4/22 5:30:57 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion

      SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Dr. Carlos V. Paya, chairman of Fluidigm, said, "On behalf of the Board of Directors, I would like to thank our stockholders for their support of this investment, which is expected to fuel a realization of identified growth and cost opportunities within the Company's two major platforms, mass cytometry and microfluidics, and pave the way

      4/1/22 4:05:00 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Financials

    Live finance-specific insights

    See more
    • Fluidigm Announces Third Quarter 2021 Financial Results

      Board Undertaking Review of Range of Value-Enhancing Opportunities SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the third quarter ended September 30, 2021. "We saw a very active third quarter and made progress with our ambitious plan to commercially scale two new instrument systems," said Chris Linthwaite, President and CEO. "Core demand for our products was healthy, but we were unable to fulfill all orders for our products during the quarter, largely due to supply chain issues. Our b

      11/8/21 4:02:00 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Announces Conference Call and Webcast of Third Quarter 2021 Financial Results

      SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on November 8, 2021, to discuss third quarter 2021 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call. Individuals int

      10/20/21 8:30:00 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 Million

      Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million. SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the second quarter ended June 30, 2021. "Second quarter results were driven by a rebound in our base business and early customer orders following the launch of our new fourth generation CyTOF® XT mass cytometry product," said Chris Linthwaite, President and CEO. "Our services busines

      8/5/21 4:05:00 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods